Claim Missing Document
Check
Articles

Found 3 Documents
Search

A Hepatoblastoma in Four-Year-Old: Diagnosis and Chemotherapy Treatment Destianti E, Eka; Indriyani, Fonna
Indonesian Journal of Cancer Vol 19, No 2 (2025): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i2.1253

Abstract

Introduction: Hepatoblastoma is a primary liver malignancy that often occurs in children under 5 years of age. According to the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of liver tumors in children is estimated to be 0.47 (0.24–0.65)/1,000,000/year. The International Society of Pediatric Oncology Liver Tumor Study states that childhood liver cancer may be sensitive to chemotherapy. Chemotherapy strategies rely on cisplatin, as it remains the most active single agent against hepatoblastoma. In this study, we aim to discover of diagnosis and outcome of hepatoblastoma patients treated with cisplatin chemotherapy. Case Presentation: This case reports a pediatric patient aged 4 years 3 months 13 days with complaints of an enlarged stomach. The results of physical examination, laboratory, radiology, and anatomical pathology results showed the presence of hepatoblastoma. The patient is currently undergoing cisplatin chemotherapy. Diagnosis of hepatoblastoma is based on clinical features, increased serum AFP levels, radiological images, and anatomical pathology. The International Society of Pediatric Oncology Liver Tumor Study states that childhood liver cancer may be sensitive to chemotherapy. Chemotherapy strategies rely on cisplatin, as it remains the most active single agent against hepatoblastoma.Conclusion: This study discusses the diagnosis and response to chemotherapy in hepatoblastoma patients. Given the limited data in this case, it is recommended to carry out further research regarding the side effects of chemotherapy for hepatoblastoma.
A Decade of KDIGO updates (2012–2025): What’s new in the evaluation and management of anemia in chronic kidney disease? Indriyani, Fonna; Wahyudi, Hendra
Svāsthya: Trends in General Medicine and Public Health Vol. 2 No. 5 (2025): September 2025
Publisher : PT. Mega Science Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70347/svsthya.v2i5.110

Abstract

Anemia is a prevalent complication of chronic kidney disease (CKD) that leads to adverse clinical outcomes, increased rates of morbidity and mortality, and increased healthcare costs. The recently updated KDIGO 2025 Anemia in CKD Guideline substantially updates the 2012 version, incorporating the latest clinical evidence and expert consensus to improve patient care in CKD patients. This review examines the updates in the KDIGO 2025 Anemia in CKD Guideline compared with the 2012 version, highlighting advancements in diagnosis, evaluation, and management to improve patient outcomes. A comprehensive analysis of the published literature, guideline updates, and clinical studies was conducted to assess changes in the diagnostic and evaluation criteria, treatment approaches, and therapeutic recommendations for anemia in CKD patients. The diagnosis and evaluation of anemia in CKD emphasize a more individualized, risk-based approach that considers the patient’s stage of CKD. Optimizing iron status and addressing inflammation before initiating ESA therapy should be prioritized to minimize the risk of complications. HIF-PHIs are alternative therapies for patients with ESA resistance or an increased risk of ESA-related complications. A structured framework for managing ESA hyporesponsiveness can classify high-risk patients and promote alternative interventions, such as iron optimization and HIF-PHIs, instead of ESA dose escalation. The updated guidelines largely maintain unchanged transfusion practices. The KDIGO 2025 guidelines represent a major evolution in the evaluation and management of anemia in CKD patients, building on the 2012 recommendations with more precise and individualized treatment strategies. These updates optimize treatment efficacy, reduce complications, and enhance patient outcomes.
Risk Factors Computer Vision Syndrome in Computer Engineering Students, Syiah University of Kuala Indriyani, Fonna; Basri, Saiful; Wahyu Asrizal, Cynthia
Journal Research of Social Science, Economics, and Management Vol. 1 No. 9 (2022): Journal Research of Social Science, Economics, and Management
Publisher : Publikasi Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59141/jrssem.v1i9.159

Abstract

Computer Vision Syndrome (CVS) is a collection of symptoms related to computer use prolonged. This can occur from various factors consisting of individual factors, computer factors and environmental factors. Computer engineering students are a group of students who use computers in doing assignments and other activities in daily life. The purpose of this study was to determine the risk factors for CVS events in students of the Computer Engineering Study Program, Syiah Kuala University. This research is an observational analytic survey with a cross sectional. The sample used consisted of 164 students from the 2017-2019 class who were taken by the stratified random sampling method. Collecting data through self-assessment using a questionnaire. Statistical test using Chi square test for bivariate and to find out which risk factor is the most influential, multivariate analysis is used, namely logistic regression analysis. The results showed that 63.4% of Computer Engineering Students at Syiah Kuala University experienced CVS. The factors that were significantly associated with the incidence of CVS were gender (p=0.03), duration of computer use (p=0.01) and eye distance to the monitor (p=0.001).